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Background: Several findings suggest that the amyloid precursor protein (APP) and the 
amyloid cascade may play a role in motor neuron disease (MND).
Objective: Considering that dementia is one of the most frequent non-motor symptoms 
in amyotrophic lateral sclerosis (ALS) and that hippocampus is one of the brain areas 
with greater presence of amyloid-related changes in neurodegenerative diseases, our 
aim was to analyze the molecular markers of the amyloid cascade of APP in pathology 
studies of the hippocampus of autopsied patients with ALS and ALS–frontotemporal 
dementia (FTD).
Methods: We included nine patients with MND and four controls. Immunohistochemical 
studies and confocal microscopy were used to analyze the expression of APP, TDP-43, 
pho-TDP-43, Aβ, APP intracellular cytoplasmatic domain (AICD) peptide, Fe65 protein, 
and pho-TAU in the hippocampus of seven patients with ALS, two patients with ALS–
FTD, and four controls. These findings were correlated with clinical data.
results: Patients displayed increased expression of APP and Aβ peptide. The latter was 
correlated with cytoplasmic pho-TDP-43 expression. We also found decreased Fe65 
expression. A parallel increase in AICD expression was not found. Patients showed 
increased expression of pho-TAU in the hippocampus. Findings were similar in patients 
with ALS and those with ALS–FTD, though more marked in the latter group.
conclusion: Post-mortem analyses showed that the amyloid cascade is activated in 
the hippocampus of patients with MND and correlated with cytoplasmic pho-TDP-43 
expression. The number of intracellular or extracellular aggregates of Aβ peptides was 
not significant.
Keywords: amyotrophic lateral sclerosis, frontotemporal dementia, amyloid precursor protein, aβ peptide, aicD 
peptide, TDP-43, TaU protein, Fe65 protein
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inTrODUcTiOn
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative dis-
ease affecting motor neurons in the brain, brainstem, and spinal 
cord. Its prevalence rate is estimated at 4–6 cases per 100,000 
population (1). It has a variable clinical course, and onset is 
usually focal (more frequently spinal than bulbar). Life expec-
tancy is estimated at 3–5 years on average. Although the cause 
is unknown, it has been linked to mutations in different genes 
even in the sporadic forms (2). Pathology studies in patients with 
ALS have shown that degeneration not only affects motor areas 
but also the dorsolateral prefrontal cortex, anterior cingulate, hip-
pocampus, dentate gyrus (DG), parietal lobe, substantia nigra, 
cerebellum, amygdala, and basal ganglia (3).
The copresence of several neurodegenerative diseases in some 
patients has led to defining new groups of diseases, some of which 
are linked to certain genetic or molecular markers. For example, 
the association between ALS and certain forms of frontotemporal 
dementia (FTD) has been linked to TDP-43 positive cytoplasmic 
inclusions as well as to mutations in the gene encoding this pro-
tein or other related proteins, in both familial and sporadic forms 
whether these molecular changes are a cause or a consequence 
of neuronal degeneration is unclear (4–7). Although the associa-
tion between ALS and Alzheimer disease (AD) has not been well 
studied, some authors have suggested that these entities may 
co-occur. Although the association between ALS and AD has not 
been well studied, some authors have suggested that these entities 
may co-occur (8–17).
Although patients with ALS may also present memory 
impairment and even dementia (18), only two pathology stud-
ies have analyzed the presence of changes compatible with AD. 
In a series of 30 patients with ALS, Hamilton and Bowser (19) 
found a prevalence of dementia of 24.1%. Around 30% of the 
patients displayed pathological changes associated with AD, 
especially amyloid and neuritic plaques in the hippocampus, 
which were more common in the DG and neocortex. These 
authors also found patients without dementia who showed AD 
lesions; Aβ deposition was present in up to 50% of cases. In that 
study, pathological changes of AD, especially neuritic plaques, 
were associated with older age and shorter survival time (20). In 
another study, Coan and Mitchell (20) analyzed 46 autopsies of 
patients with ALS and found that 22% of the cases met criteria 
for AD and 26% for FTD, 78% displayed neurofibrillary tangles, 
and 35% showed moderate increases in Aβ expression, especially 
in the amygdala, hippocampus, and the entorhinal and insular 
cortices. Likewise, ALS onset in patients who met the criteria for 
AD was more frequently bulbar; onset type had no impact on 
survival time. All patients with Aβ peptide accumulation showed 
greater prevalence of neurofibrillary tangles in the hippocampus 
and amygdala. Furthermore, the form of ALS reported in Guam 
residents is associated with abundant neurofibrillary tangles in 
addition to the classic neuropathological findings of the disease 
(21, 22).
Amyloid cascade is defined by the consequences of amyloid 
precursor protein (APP) cleavage after two successive proteolysis, 
which has served as the basis for the amyloid hypothesis of AD 
(23), and finally produces Aβ. While β- and γ-secretases promote 
Aβ formation, α-secretase has the opposite effect, which results 
in two pathways: the amyloidogenic and the non-amyloidogenic 
APP pathways, respectively. The last proteolysis in the amyloido-
genic pathway produces two substrates: the peptides Aβ and the 
APP intracellular cytoplasmatic domain (AICD), which plays an 
important role in the transcriptional regulation of certain genes. 
The idea that certain pathological changes of AD may be present 
in patients with ALS or ALS–FTD suggests the possibility that 
they have common mechanisms (24), but it may also indicate 
that these changes are not primary (25). Patients with ALS do not 
generally present clinical changes as intense amnestic symptoms 
suggesting that the hippocampus could be significantly affected, 
contrary to what occurs in AD. Taking into consideration that 
the hippocampus is one of the areas of the brain most affected by 
molecular changes associated with AD, we analyzed the expres-
sion of proteins linked to the amyloid cascade in the hippocampus 
of autopsied patients with ALS or ALS–FTD.
MaTerials anD MeThODs
selection and study of Patients and 
controls
We analyzed the autopsies of nine patients that were included 
in the ALS registry of our neurology department. This registry 
follows a protocol for diagnosing and treating ALS that includes 
clinical assessment, electromyographic and neuroimaging stud-
ies, and blood and CSF analyses, as well as criteria for assessing 
FVC and using BiPAP, and indicating gastrostomy and riluzole 
(26). These patients, who died between 2006 and 2012, met the El 
Escorial revised and Ludolph criteria for ALS (27, 28). The follow-
ing clinical variables were included in our analysis: age, sex, disease 
duration, clinical form, whether riluzole was administered, and 
clinical data related to potential cognitive impairment. Data were 
gathered from the ALS registry by thoroughly reviewing clinical 
histories and conducting telephone interviews with the patients’ 
relatives. Eight of the patients included in our study had died of 
respiratory failure at the terminal stage of ALS. The remaining 
patient died due to cardiac arrest upon admission after attending 
the hospital due to progressive dysphagia and moderate bulbar 
involvement and being diagnosed with ALS. Our controls were 
four patients who died at a hospital due to a non-neurological 
disease. They were included because their families had consented 
to donation of the body. None of them had a history of neurode-
generative diseases. We reviewed their medical records to rule 
out a history of neurological disease. One of our controls was 
donated by another center; we were therefore unable to review the 
medical history but confirmed that the patient had not died from 
a neurological cause and had no history of neurodegenerative 
disease.
autopsy Procedure and Preparation and 
storing of Biological Material
Autopsies were performed within 2–6  h after death following 
our hospital’s standard protocol and in compliance with Spanish 
regulations for this procedure. We followed the standard 
method: opening the cranial cavity and severing the upper 
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end of the spinal cord at the foramen magnum. To separate the 
hemispheres, we cut right along the midline of the corpus cal-
losum and prepared them for later sectioning. Tissue samples 
were fixed in 10% buffered formalin [phosphate-buffered saline 
(PBS); 0.1M, pH 7.35]. The hemisphere allocated to histological 
and immunohistochemical analyses was sectioned into coronal 
slices (maximum slice thickness = 1 cm), which were placed on a 
flat surface in order from the frontal pole to the occipital pole. The 
nervous system analysis included weighing the brain, examining 
its macroscopic morphology, and conducting a microscopic 
study, using conventional techniques. In all cases, the study 
included hematoxylin-eosin and Nissl staining. Additional 
techniques were used at the discretion of the pathologist, includ-
ing Congo red and silver staining to determine the presence of 
such macroscopic and microscopic alterations as atrophy, senile 
plaques, eosinophilia, or neuronal loss. Thioflavin-S staining was 
used for all cases and controls.
study of the hippocampus
Once the tissue for microscopic analysis had been adequately pre-
pared, paraffin blocks were sectioned to obtain the hippocampus, 
which should include at least the following areas: CA1, CA2, CA3, 
and DG. All tissue samples were embedded in paraffin following 
the protocol established by the pathology department at our hos-
pital and subsequently sectioned to study the cytoarchitecture of 
the hippocampus. We used Braak staging, which was developed 
by Braak and Braak (29), to assess pathological findings.
immunohistochemical study
Tissue was sectioned into 6-μm slices using a microtome (Leica). 
Slices were deparaffinized and thoroughly washed with PBS 
0.1M. Epitopes were unmasked in a 10-mM sodium citrate 
buffer with a pH of 6 at 96°C for 30 min. Samples destined for 
APP immunostaining were additionally incubated for 20  min 
in formic acid v/v. Following this, all samples were incubated 
in a blocking solution (PBS, 0.2 Triton X-100, 10% normal goat 
serum) for 1  h. After that, tissues were incubated in primary 
antibodies diluted in PBS for 24  h. After incubation with pri-
mary antibodies, sections were washed with PBS and incubated 
in the appropriate HRP or Alexa-Fluor secondary antibody (see 
Table S1 in Supplementary Material). For APP and phospho TAU 
antibodies, goat anti-rabbit HRP was used, the sections were 
stained brown with a DAB-peroxidase solution of 0.03% diam-
inobenzidine and 0.01% H2O2, and counterstained with Nissl 
staining. They were subsequently mounted in DPX and observed 
under a ZEISS microscope. For the immunofluorescence study 
of the other markers, tissue sections were thoroughly washed 
and incubated with the appropriate Alexa-Fluor antibody for 
24 h after incubation with primary antibodies. After thoroughly 
washing the sections, they were mounted in ProLong Gold 
reagent with DAPI (Molecular Probes, Invitrogen) and observed 
in an Olympus confocal microscope AF2000. Five hippocampal 
slides were used, those containing CA1–3 and DG (separated by 
at least 200 μm each, to avoid double quantifications), and the 
quantitative study included the analysis of 10 different fields for 
each of the analyzed antibodies; the result was the mean of the 
10 measurements. In the cases where the unit of measurement 
was the amount of labeling per field [optical density (OD)], we 
used Image J software version 1.46r, developed by the National 
Institutes of Health. In the cases where inclusions were assessed, 
these were quantified based on the number of stained inclusions 
that were found in neurons divided by the mean number of 
neurons per field (percentage of cells in 500 μ2).
statistical analysis
Statistical analysis was performed using SPSS statistical software 
version 20.0. Results were represented graphically using GraphPad 
Prism version 5.0. Data are expressed as mean ± SD. Means were 
compared using the non-parametric Mann–Whitney U test due 
to the small sample size. Graphs were created using the program 
mentioned above. Statistical significance was set at p < 0.05.
resUlTs
Description of the study sample
Our study included nine patients (seven with ALS and two 
with ALS–FTD) and four controls. Five patients were men 
(56%), and four were women (44%). Mean age at diagnosis was 
64.56 ± 16.8 years, and mean age at death was 65.33 ± 15.7 years. 
Regarding the controls, there were three men (75%) and one 
woman (25%), with a mean age at death of 68.75 ± 14.86 years. 
Six of the nine patients had an additional disease: one had a 
history of stroke, one had ulcerative colitis, two had a history of 
depression, one presented essential tremor, and the remaining 
one had REM sleep behavior disorder. Only one of the patients 
had a first-degree relative with a history of dementia of unknown 
origin. Likewise, only one patient presented a familial form of 
ALS. This patient, who had a non-pathological SOD1 mutation, 
had been included in a previous study (30). Mean time elapsed 
from onset of motor/bulbar symptoms to diagnosis of ALS was 
6.44 ± 3.9 months (not including the two cases with ALS–FTD). 
Disease onset was bulbar in five patients (56%) and spinal in the 
remaining four (44%). Seven patients (78%) had received rilu-
zole and six (67%) required permanent mechanical ventilation; 
mean time elapsed from diagnosis to indication of mechanical 
ventilation was 9  months. Five patients (56%) were being fed 
by gastrostomy. Mean time elapsed from onset of motor/bulbar 
symptoms to death was 17.6 ± 16.5 months (we did not count 
the time the two patients with FTD had presented impairment 
linked to FTD before ALS onset) and 11.11 ± 15.6 months from 
diagnosis to death. Cognitive disorders were only reported in the 
patients with ALS–FTD. Patient histories and clinical character-
istics are shown in Table S2 in Supplementary Material.
Description of general Pathological 
Findings in the autopsies
Table S3 in Supplementary Material summarizes the results 
of the neuropathology study and shows the fixed brain weight 
for each subject. No significant differences were found in brain 
weight between patients with ALS (1220 ± 147 g) and controls 
(1290 ± 72.73 g; p = 0.244). Neuropathological findings resulted 
in a diagnosis of motor neuron disease (MND) in all patients. 
From a macroscopic point of view, precentral gyrus atrophy was 
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seen in patients eight and nine and none of the controls. Likewise, 
two patients, and none of the controls, displayed thinning of the 
ventral roots of the spinal cord; all patients showed considerable 
neuronal loss in the anterior horn of the spinal cord. One of 
the patients exhibited loss of motor neurons in the medulla 
oblongata. One patient displayed numerous neurofibrillary 
tangles and amyloid plaques, while another showed moderate 
extracellular amyloid deposition. Ubiquitinated inclusions were 
found in the hippocampus and spinal cord of five patients. The 
mean number of neurons with ubiquitin-positive inclusions 
was 0.5 ± 0.58 in controls and 7.43 ± 2.7 in patients (p = 0.007), 
or 7.67 ±  0.8 if we exclude the patients with FTD (p =  0.01) 
(data expressed in 500 μm2 field).
cytoplasmic Phosphorylated TDP-43 
expression is increased in the 
hippocampus of Patients with 
als and als–FTD
TDP-43 is a transcription factor that is located in the nucleus of 
cells. In MNDs, this protein is cleaved and translocated to the 
cytoplasm, where it may be phosphorylated. TDP-43, like ubiq-
uitin, can be observed in cytoplasmic inclusions, leading to the 
idea of “TDP-43 pathology,” which encompasses such diseases 
as ALS and ALS–FTD. This protein is also found in the cyto-
plasm of neurons in patients with AD. In our sample, the mean 
percentage of expression of cytoplasmic phosphorylated TDP-
43 (pho-TDP-43) in the hippocampus was higher in patients 
than in controls, which confirms that this area is affected. The 
area of the hippocampus showing the greatest TDP-43 expres-
sion was CA1, followed in decreasing order by GD, CA3, and 
CA2 (data not shown). The mean percentage of hippocampal 
cells with TDP-43-positive inclusions was 20.15 ± 10.46 (range 
6.5–33.34) in the patient group and 1.62 ± 1.45 (range 0–2.67) 
in the control group. All patients displayed increased pho-
TDP-43 expression, compared to controls; differences between 
patients and controls were statistically significant (p = 0.0028). 
Comparing ALS patients with ALS–FTD patients is not feasible 
since our sample included only two patients with ALS–FTD; 
however, higher pho-TDP-43 expression was observed in 
the ALS–FTD group. These data can be seen in Figure S1 in 
Supplementary Material.
aPP expression is increased in the 
hippocampus of als and als–FTD 
Patients but is not correlated with  
TDP-43 expression
Amyloid precursor protein is a ubiquitous transmembrane, 
type-1, integral glycoprotein of 110–130 kDa that is extensively 
expressed in human tissues. In the CNS, some functions attrib-
uted to APP are neurite outgrowth and synaptogenesis, protein 
trafficking along axons, cell adhesion, calcium metabolism, and 
signal transduction (31). Mean APP expression was higher in the 
hippocampus of our patients [4345 ± 1975 (range 3832–8204) 
OD] compared to controls [1925  ±  309 (range 1761–2458) 
OD]. APP expression was increased in all patients; differences 
between patients and controls were statistically significant 
(p  =  0.0028). APP expression was greater in patients with 
ALS–FTD. These data are summarized in Figure  1. APP 
expression in the hippocampus was not correlated with phospo 
TDP-43 expression (r = 0.20), as shown in Figure 2A, and APP 
did not co-localize with TDP-43 in the cytoplasm (data not 
shown). Considering that APP plays an important role in cell 
survival, increased APP expression may be a cell response to 
neurodegeneration. However, the hippocampus is not clinically 
affected in ALS; the correlation found between APP and TDP-43 
supports this hypothesis. The amyloid cascade of APP is active 
in the hippocampus in patients with MND and correlates with 
pho-TDP-43 expression.
The successive activity of two proteolytic processes, involving 
β- and γ-secretase, respectively, produces Aβ peptides, mainly 
Aβ40 and Aβ42. These may form oligomers and insoluble fibrils 
that accumulate both intracellularly and in extracellular amy-
loid plaques. This latter represents the pathological substrate 
for AD since Aβ peptide secretion plays a role in regulat-
ing neurotransmitter release in the synapses (32). Increased 
intracellular Aβ expression indicates greater amyloid cascade 
activity. Mean intraneuronal Aβ expression in the hippocampus 
was higher in patients than in controls: 32,261 ± 25,720 (range 
7431–79,676) OD vs. 5393 ± 2048 (range 3542–8270) OD. All 
but one patient showed increased Aβ expression; differences 
between patients and controls were statistically significant 
(p = 0.0056). Greater APP expression was observed in one of 
the patients with ALS–FTD. These data are shown in Figure 3. 
The areas of the hippocampus showing increased intraneuronal 
Aβ expression were, in descending order, CA1, GD, CA3, 
and CA2 (data not shown). Although scarce, we observed 
Aβ deposits in the form of dense, diffuse plaques. Similar to 
what occurred with APP and cytoplasmic pho-TDP-43, Aβ 
expression and cytoplasmic pho-TDP-43 expression were 
moderately correlated (r  =  0.530) (Figure  2B) but did not 
co-localize (data not shown). This correlation suggests that 
there is a link between cytoplasmatic pho-TDP-43 and activa-
tion of the amyloid cascade of APP in the hippocampus of 
patients with MND.
expression of aicD is Variable in MnD
Amyloid precursor protein intracellular cytoplasmatic domain, 
the substrate common to both APP pathways, results from the 
activity of γ-secretase on sAPPα or sAPPβ; these soluble interme-
diate fragments are generated by α- and β-secretase, respectively 
(33, 34). This peptide forms a complex with adaptor protein Fe65 
and histone acetyltransferase Tip60, and this complex plays an 
important role in regulating transcription of the genes encoding 
such proteins as APP, β-secretase, KAI1 (CD82), neprilysin, 
and p53 (35). In our sample, mean AICD expression in the 
hippocampus of patients was significantly raised compared to 
controls (p = 0.02); however, the expression was not elevated in 
three patients (Figure 4). The mean number of hippocampal cells 
showing AICD expression per area analyzed was 15 ± 3.18 (range 
9–18) in patients and 8 ± 2.58 (range 5–11) in controls; patients 
with ALS–FTD displayed even higher numbers. These data are 
shown in Figure S2 in Supplementary Material. Wang et al. (36) 
FigUre 1 | aPP expression (a) in mean values ± sD and individual values for controls and patients [(a,D), respectively] and immunohistochemistry 
images from controls (B) and patients (c). Patients show a statistically significant increase (*) in APP expression compared to controls, which may indicate that 
the amyloid cascade of APP is activated as a protective mechanism against the pathological effects of ALS. Photomicrographs (B,c) show the differences in 
labeling between controls and patients; as can be observed, APP expression (arrows) is greater in patients (c). (D) Shows the individual data corresponding to 
patients and controls; APP expression is greater in patients than in controls, regardless of whether they had ALS or ALS–FTD. Scale bar: 50 μm. The dotted line 
indicates the significance threshold. The graphs display mean optical density (arbitrary units).
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demonstrated that AICD binds to and co-localizes with TDP-43 
in the nucleus of cultured HEK293 cells. In our study, we nei-
ther found a significant correlation between AICD expression 
and cytoplasmic pho-TDP-43 expression nor did we observe 
 co-localization between the two (data not shown).
Fe65 expression is lower in 
Patients with MnD
Highly expressed in the hippocampus (37), Fe65 is an adaptor 
protein that is thought to play a crucial role in modulating 
the amyloid cascade of APP (38–42). Fe65 promotes the APP 
cascade by increasing Aβ production; this mechanism is 
attenuated by Fe65 phosphorylation (43). Mean Fe65 expres-
sion in hippocampal cells was significantly lower in patients 
[14 ± 3.37 (range 8–19)] than in controls [22.5 ± 3.37 (range 
21–29)] (p  =  0.018). None of the patients presented levels 
similar to those found in controls. Within the patient group, 
Fe65 expression was higher in patients with ALS–FTD. These 
findings (Figure  5) suggest that decreased Fe65 expression is 
probably due to phosphorylation in an attempt to decrease Aβ 
production. Cell labeling of Fe65 was at times weak or diffuses 
in the nucleus. The areas with greater positive immunoreactiv-
ity were, in descending order, DG, CA1, CA3, and CA2. Fe65 
expression is inversely correlated with that of APP, AICD, and 
TDP-43 (Figure S3 in Supplementary Material), which supports 
the hypothesis that the amyloid cascade is activated in the hip-
pocampus of patients with MND.
Pho-TaU is expressed to a More Marked 
Degree in the hippocampus of Patients 
with als
TAU is overexpressed in patients with AD and other neurode-
generative diseases. TAU phosphorylation and aggregation is the 
molecular basis of neuritic plaques (44, 45). In our study, mean 
cell expression of hippocampal pho-TAU s396 was significantly 
increased in patients compared to controls (p = 0.002); none of 
FigUre 2 | correlation between cytoplasmic pho-TDP-43 expression and aPP expression (a) and between cytoplasmic pho-TDP-43 expression and 
aβ expression (B). No correlation was found between pho-TDP-43 and APP. We observed a moderate correlation between pho-TDP-43 and Aβ.
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the patients showed similar levels to those displayed by controls. 
Patients had a mean OD of 21,431 ± 21,455 (range 7431–73,844) 
and controls, 3278 ± 1378 (2481–5534). Pho-TAU s396 expres-
sion, which was slightly greater in patients with ALS–FTD 
(Figure  6), was shown to be inversely correlated with AICD 
expression (r = 0.570) (Figure S4 in Supplementary Material). 
A possible explanation for this correlation is provided by a 
study in which AICD-overexpressing transgenic mice showing 
no increase in Aβ levels displayed greater TAU expression and 
protein aggregation (46). The explanation for this is that AICD 
peptide upregulates GSK-3β expression, GSK-3β activation, and 
consequently TAU phosphorylation in rat neuronal cultures 
(47). This suggests that AICD induces TAU expression.
correlations with clinical Profile 
and Progression
Despite the small number of patients included in our study, 
we correlated immunopathological findings with clinical char-
acteristics and progression. These data are shown in Figure S5 
in Supplementary Material. There is a statistically significant 
inverse correlation between total TDP-43 levels and time elapsed 
from diagnosis to death (r = 0.75), and between the percentage 
of cytoplasmic TDP-43 and time to indication of mechanical 
ventilation (r = 0.69). According to this latter correlation, greater 
levels of cytoplasmic TDP-43 are associated with a poorer prog-
nosis. Likewise, increased expression of pho-TDP-43 and AICD 
are associated with bulbar onset (pho-TDP-43: 16.20 vs. 11.35% 
of cells with TDP-43-positive inclusions; AICD: 15.8 vs. 11.5, 
mean number of cells per analyzed area). Three patients showed 
increased pho-TAU s396 expression, which was associated with 
increases in AICD. Pho-TAU s396 overexpression was associ-
ated with more advanced Braak stages and greater quantities of 
thioflavin-S stained fibers.
Comparing immunopathology findings with the clinical 
forms of the disease showed that bulbar forms were associated 
with greater AICD (p = 0.031) and TDP-43 (p = 0.020) expres-
sion. We observed no significant differences in the expression of 
the remaining markers. Despite the small number of patients with 
ALS–FTD, the percentage of cytoplasmic TDP-43 was found to 
be greater in that subgroup (p = 0.0475).
The expression profile of markers showed no significant 
differences between patients with survival times shorter than 
12 months and those with longer survival times. Higher levels of 
TDP-43 were correlated with shorter survival times (r = 0.753), 
as shown in Figure S5 in Supplementary Material.
DiscUssiOn
There are many studies in the literature suggesting that neurode-
generative diseases share molecular characteristics; however, few 
studies have addressed this hypothesis with regard to AD and 
ALS (8, 19, 20). Findings from different studies point to certain 
common mechanisms. For example, Aβ accumulation has been 
found in the spinal cords of patients with both the familial and 
sporadic forms of ALS (48) as well as in the skin and muscles 
of ALS patients (49, 50), and biomarkers linked to the amyloid 
cascade have been found in the CSF of patients with ALS and FTD 
(49). In addition, increased APP expression has been observed in 
spinal cord motor neurons in experimental models in the early 
stages of ALS (51–54), and some experimental models of AD have 
displayed extracellular Aβ plaques in motor neurons, similar to 
those found in humans with AD (55). Likewise, increased Aβ 
expression has been found in affected motor neurons and the sur-
rounding glial cells in SOD1G93A mouse models; genetic ablation 
of APP in these mice reduces motor neuron degeneration (56). 
These findings are the reason for our interest in understanding 
FigUre 3 | aβ expression (a) in mean values ± sD and individual values for controls and patients [(a,D), respectively] and immunohistochemistry 
images from controls (B) and patients (c). Patients displayed a statistically significant (*) increase compared to controls, which suggests that Aβ levels are higher 
in the hippocampus of patients with ALS. Photomicrographs (B,c) (dentate gyrus) show the differences in labeling between controls and patients; as can be 
observed, expression of Aβ-positive plaques is greater in patients (c) than in controls (B). (D) Shows the individual data corresponding to patients and controls. Aβ 
expression is greater in patients; the highest value corresponds to a patient with ALS–FTD. Scale bar: 50 μm. The dotted line indicates the significance threshold. 
The graphs display mean optical density (arbitrary units).
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biomarker expression in the amyloid cascade of APP and the 
connection with TDP-43 in patients with ALS.
Some clinical data, especially cognitive and neuroimaging 
findings, suggest that the hippocampus is affected in ALS (57, 58). 
Some authors have even proposed that hippocampal involvement 
in ALS has a different, less marked, pattern to that associated 
with AD degeneration (59, 60). Our aim was to study molecular 
alterations in the hippocampus, since this area shows no clinical 
changes in ALS but is greatly affected in AD patients. We found 
increased expression of cytoplasmic TDP-43 and pho-TDP-43, 
which confirms that ALS affects the hippocampus at a molecular 
level. Increased levels of TDP-43 in the hippocampus have been 
reported in previous studies, although they were linked to long 
disease progression times (61, 62). This is not applicable to our 
patients, who presented a short mean survival time (17.6 months 
from symptom onset). In any case, the presence of both cyto-
plasmic TDP-43 and pho-TDP-43 indicates that the mechanisms 
of neurodegeneration are active in the hippocampus of patients 
with MND.
Our study shows that the amyloid cascade of APP is activated 
and expressed in the hippocampus via its molecular markers in 
both ALS and ALS–FTD, as we found increased expression of 
APP and Aβ peptides, and even pho-TAU s396 overexpression. 
This increase in Aβ peptides is correlated with the expression of 
cytoplasmic pho-TDP-43 peptides. These data may suggest that 
APP expression and amyloid cascade activation are a response to 
molecular changes caused by MND: increased APP expression 
may be a mechanism of cell survival.
Our patients showed reduced Fe65 expression, probably due 
to the fact that Fe65 binds to AICD to downregulate APP expres-
sion. The hypothesis that Fe65 forms a complex with AICD is 
reinforced by the fact that, in some patients, increases in Fe65 
expression were not present as would be expected considering that 
Fe65 production is simultaneous to that of Aβ after γ-secretase 
FigUre 4 | aicD expression (a) in mean values ± sD and individual values for controls and patients [(a,D), respectively] and immunohistochemistry 
images from controls (B) and patients (c). Patients displayed a statistically significant (*) increase compared to controls, which indicates that AICD levels are 
higher in our patient sample. Photomicrographs (B,c) show the differences in labeling between controls and patients; AICD expression (arrows) is greater in patients 
(c) and low in controls (arrow). (D) Shows individual data for patients and controls. AICD expression is increased in patients: six patients (both with ALS and 
ALS–FTD) show higher values than those of controls. Scale bar: 20 μm. The dotted line indicates the significance threshold. The graphs present the percentage of 
cells with immunopositive inclusions in 500 μ2.
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activity. We also found increased expression of pho-TAU in the 
hippocampus in all cases. Although it has been suggested that 
increased TAU expression is linked to AICD production (63), we 
found no correlation between the two. It is therefore most likely 
due to increased intraneuronal Aβ expression.
Our findings appear to confirm the hypothesis that the amy-
loid cascade of APP is activated in the hippocampus of patients 
with ALS and ALS–FTD. However, thioflavin-S staining in some 
of the patients revealed few intracellular or extracellular Aβ 
aggregates. This is consistent with in vivo findings from a previous 
study using PET with 18F-florbetaben, which reported low tracer 
uptake in the hippocampus of patients with ALS (64). This may 
be explained by the fact that this tracer binds to Aβ deposits and 
fibers and does not detect increases in peptide expression (65), 
as shown in our pathology study. However, some studies on ALS 
have shown amyloid tracer uptake (66–68). For instance, one 
study found tracer uptake in elderly patients (69). We hypothesize 
that a cohort of patients with longer survival times may present 
longer cascade activation periods, which may in turn lead to a 
greater presence of aggregates that PET imaging or thioflavin 
staining would detect.
Molecular changes found in the hippocampus are not linked 
to a specific clinical profile and progression pattern. Increased 
expression of AICD was only found in bulbar ALS; however, 
the significance of this finding is difficult to interpret. Greater 
expression of total or cytoplasmic TDP-43, which occurs in bul-
bar onset ALS and ALS associated with FTD, is correlated with 
poorer prognosis, meaning shorter survival time from diagnosis 
or shorter time elapsed to indication of mechanical ventilation. 
This idea is in line with studies suggesting that the measurement 
of TDP-43 may be a prognostic biomarker of the disease (70), 
although several other studies show elevations in CSF cannot be 
considered a sensitive diagnostic marker at that moment (71, 72).
Our study has a number of limitations. First, the included 
patients are representative of the most severe forms of the disease 
(high percentage of bulbar onset ALS and short survival time), 
FigUre 5 | Fe65 expression (a) in mean values ± sD and individual values for controls and patients [(a,D), respectively] and immunohistochemistry 
images from controls (B) and patients (c). Patients displayed a statistically significant (*) decrease in Fe65 expression compared to controls, which indicates that 
Fe65 levels are lower in our patient sample. Photomicrographs (B,c) show the differences in labeling between controls and patients; Fe65 expression is greater in 
patients (c) than in controls (B), who display mild, diffuse labeling (arrow) and show nuclear expression (red arrow). (D) Shows individual data for patients and 
controls: controls display increased Fe65, and all patients show values below the statistical mean. Scale bar: 50 μm. The dotted line indicates the significance 
threshold. The graphs present the percentage of cells with immunopositive inclusions in 500 μ2.
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since all of them were bodies that had been donated. We therefore 
cannot rule out the premise that the degree to which the amyloid 
cascade is activated depends on the intensity of neurodegenera-
tion. This hypothesis is also supported by the fact that changes 
seemed to be more intense in patients with ALS–FTD than in 
those with ALS. Studies with greater sample sizes are necessary 
to confirm this idea. Furthermore, this limitation added to a 
sample of patients with short survival times does not allow us to 
evaluate the extent to which the amyloid cascade affects the hip-
pocampus over longer time periods. The convenience of increase 
in the sample is particularly necessary in the subgroup of patients 
with FTD/ALS, where the small number of cases does not allow 
statistical analysis in any molecular marker, such as cytoplasmatic 
TDP-43. Second, autopsies were performed 2–6  h after death 
since these patients rarely die in hospital and must therefore be 
transported from their homes or palliative care centers. This time 
window may have had some impact compared with those from 
animal research where the times were shorter. In addition, none 
of the patients without FTD had cognitive alterations according 
to the data from medical records and clinical histories, which was 
confirmed by telephone interviews with the patients’ relatives. 
Therefore, we cannot establish a link between cognitive altera-
tions and molecular changes in the amyloid cascade of APP in 
the hippocampus. This should be studied in a patient cohort with 
longer survival times.
In conclusion, our post-mortem analyses showed that the amy-
loid cascade of APP is activated in the hippocampus of patients 
with ALS and ALS–FTD and correlates with TDP-43 expression. 
Immunohistochemical analyses revealed no significant intracel-
lular or extracellular Aβ aggregates.
eThical sTanDarDs
The present study complies with the ethical standards of the 
research committee at our center and the 1964 Declaration of 
Helsinki and its subsequent amendments.
FigUre 6 | Pho-TaU s396 expression (a) in mean values ± sD and individual values for controls and patients [(a,D), respectively] and 
immunohistochemistry images from controls (B) and patients (c). Patients display a statistically significant (*) increase in pho-TAU s396, which may 
indicate that the mechanisms of degeneration and microtubule-mediated axonal transport are affected. This means that levels of pho-TAU s396 are raised in 
ALS. Photomicrographs (B,c) (hippocampal area CA1) show the differences in labeling between controls and patients; as can be observed, expression of 
pho-TAU is much higher in the neurons of patients (c) than in those of controls (B). (D) Shows the individual data corresponding to patients and controls. 
Pho-TAU s396 expression is greater in patients. Scale bar: 50 μm. The dotted line indicates the significance threshold. The graphs display mean optical density 
(arbitrary units).
10
Gómez-Pinedo et al. Amyloid Cascade in MND
Frontiers in Neurology | www.frontiersin.org November 2016 | Volume 7 | Article 195
aUThOr cOnTriBUTiOns
Study design: UG-P and JM-G; patient evaluation: RV-Q, LG, 
and AG-S; coordination of autopsy studies: LG; microscopy and 
molecular study: UG-P and MB-M; database: UG-P and RV-Q; 
statistical analysis: UG-P, RV-Q, and JAM-G; analysis of results: 
UG-P, JAM-G, LG, TM-R, and JM-G; figures and tables: UG-P 
and RV-Q; manuscript draft: JM-G; manuscript revision and 
approval: all the authors.
acKnOWleDgMenTs
The authors would like to thank Prof. Armando Martínez of the 
Pathology Department for his help as advisor of the work. They 
also wish to thank to translator advisory service of the Spanish 
Society of Neurology’s Research office for helping in the prepara-
tion of the manuscript.
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found online at 
http://journal.frontiersin.org/article/10.3389/fneur.2016.00195/
full#supplementary-material.
TaBle s1 | antibodies and techniques used in the study.
TaBle s2 | clinical characteristics of the patient sample. ALS, 
amyotrophic lateral sclerosis; M, male; F, female; ARF, acute respiratory failure; 
CRA, cardiorespiratory arrest; FTD, frontotemporal dementia; PPA, primary 
progressive aphasia.
TaBle s3 | general data from the pathology study of the MnD patients 
(numbers 4 and 7 were als/FTD cases). Semi-quantitative assessments. The 
scale used is 0: no alterations, +: alteration present, this alteration ++: 
moderately, this alteration +++: markedly.
FigUre s1 | expression of TDP-43 (a) and cytoplasmic pho-TDP-43 in 
mean values ± sD and individual values for controls and patients [(B,e), 
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respectively] and fluorescence images from controls (c) and patients 
(D). Although there are no differences in total TDP-43 expression (a), we found 
statistically significant differences (p = 0.0061) in the expression of cytoplasmic 
pho-TDP-43 (B). Photomicrographs (c,D) show the differences in labeling 
between controls and patients; as can be observed, cytoplasmic pho-TDP-43 
expression (arrows) is greater in patients (D). (e) Shows the individual data 
corresponding to patients and controls; expression is greater in patients than in 
controls, and that increase is even more marked in patients with ALS–FTD. 
Scale bar: 50 μm. The dotted line indicates the significance threshold. The 
graphs present the percentage of cells with immunopositive inclusions in 
500 μ2.
FigUre s2 | The directly proportional relationship between aicD and the 
expression of pho-TDP-43 (a), aPP (B), and aβ (c) is displayed.
FigUre s3 | The inversely proportional connection between Fe65 and the 
markers of the amyloid cascade is demonstrated: aPP (a), aicD (B), and 
aβ peptide (c); this suggests that Fe65 levels may be downregulated by 
mechanisms linked to aicD and the amyloid cascade.
FigUre s4 | a direct correlation between aicD peptide and pho-TaU s396 
in the hippocampus of patients with als (r = 0.570) is shown. This is 
probably due to the direct link between activation of the amyloid cascade and TAU 
phosphorylation, which is closely related to neuronal transport. This would confirm 
that both AICD and pho-TAU play a major role in the pathogenesis of ALS.
FigUre s5 | correlations between total TDP-43/cytoplasmic pho-TDP-43 
expression and such clinical variables as time to indication of 
mechanical ventilation (a), time elapsed from diagnosis to death (B), and 
age at death (c). The graph shows a weak correlation between time to 
mechanical ventilation and expression of pho-TDP-43 (r = 0.02) (a). We found a 
linear correlation between pho-TDP-43 expression and time (in months) elapsed 
from diagnosis to death (r = 0.45) (B). The correlation between total TDP-43 and 
age at death (c) was r = 0.47.
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